The completion of the trial allows Lilly to seek regulatory approval and potentially launch the next-generation drug in 2027 as it competes with Novo Nordisk in the obesity treatment market
For instance, in clinical studies, nausea was reported by up to 20-30% of patients taking GLP-1 medications like Ozempic (semaglutide) or Trulicity (dulaglutide), though symptoms often decrease as the body adjusts to the medication
Compounded Semaglutide: What to Look For Semaglutide is a medication used to treat type 2 diabetes and aid in weight loss
But when doctors do prescribe them for overlapping metabolic issues (such as insulin resistance or obesity), the most commonly recommended medications include: Semaglutide (Ozempic/Wegovy) Tirzepatide (Mounjaro/Zepbound) technically a GLP-1 + GIP dual agonist Liraglutide (Saxenda) The choice depends on: How severe metabolic symptoms are Tolerance to side effects Cost and insurance status The clinicians expertise One study looking at GLP-1associated fat changes noted that visceral fat reduction can significantly improve inflammatory biomarkers, as shown in an adipose tissue study
GLP-1 agonists might address these comorbidities while potentially influencing underlying inflammation
Liting Jiang, [email protected] These authors have contributed equally to this work and share the first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
